UroGen Pharma股价下跌,第二季度亏损超预期掩盖收入超预期

英为财情
Aug 07, 2025

Investing.com -- UroGen Pharma Ltd (NASDAQ:URGN)公布的第二季度收入超过分析师预期,但由于公司在最近产品发布相关费用增加的情况下,季度亏损超出预期,股价下跌3.3%。 这家专注于尿路上皮和特种癌症治疗的生物技术公司报告第二季度每股亏损1.05美元,未达到分析师预估的每股亏损0.83美元。收入为2420万美元,超过了2313万美元的共识预期,较去年同期...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10